Medtronic presents new data on MiniMed 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system. These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting glycemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations, found that the proprietary Meal Detection™ technology supported Time in Range outcomes that exceed consensus guidelines of 70 percent. Additionally, the system is helping reduce the percent of time spent in hyperglycemia in children and adults. These latest results were presented this weekend at the 83 rd American Diabetes Association (ADA) Scientific Sessions in San Diego, CA.

Simplified Meal Announcements with the MiniMed™ 780G System

The first study by Dr. Goran Petrovski , MD, PhD, of Sidra Medicine , randomly assigned adolescents using the MiniMed™ 780G system (n=34) into two groups, with some entering a fixed pre-set number of carbs (small, average, or high) and some calculating a precise number of carbs for their meals. These individuals had lived with diabetes for at least one year and used multiple daily injections or pump therapy prior to the study. Results from the study, which were presented Friday in an oral podium presentation, showed those using the simplified (i.e., fixed) carb entry maintained international targets for glycemic control, including an A1c of 6.9% and Time in Range (TIR) of 72.7% (vs. 79.4% TIR in the precise entry group) over 6 months without system modification. 1 Additionally, the simplified entry group lowered their time above 250 mg/dL from 28.3% to 5.3% at six months (vs. 3.9% in the precise entry group). After 3 months, 88% chose to continue with the simplified meal management approach, which suggests user satisfaction with this less burdensome approach. These results suggest that reduced accuracy in carb counting can be overcome by the increased automated insulin delivery provided by the MiniMed™ 780G system, and that even those that cannot or do not input their carbs precisely can reach glycemic goals and reduce hyperglycemia.

"Many individuals with type 1 diabetes struggle with meal management with nearly 50% considering carb counting the most burdensome aspect of diabetes management. 2 Indeed, many frequently underestimate their carbs or forget to bolus and this has an adverse impact on clinical outcomes," said Dr. Petrovski. "This study shows that a simplified meal management approach with the MiniMed™ 780G system helped users maintain glycemic targets while providing forgiveness for inexact carb counts. Clearly there's more runway for simplification of diabetes management with this system and it's promising for the many patients struggling with meal management."

Strong Real-World   Performance in Children

An analysis of real-world evidence of children ≤ 15 years in Europe and Latin America (n=3,543) using the MiniMed™ 780G system with recommended settings of 100 mg/dL and 2-hour active insulin time (AIT) demonstrated a Time in Range of 78% (Table 1). 3 A separate analysis of real-world evidence of children ≤ 15 years in Europe (n= 2,516) demonstrated improved glycemic performance in SmartGuard™ technology regardless of baseline glycemic control. 4 The group with the lowest Time in Range (poorest glycemic control) prior to SmartGuard™ technology, had the largest increase of 23.3% in Time in Range, while patients with the best metabolic control in SmartGuard™ technology achieved 80.6% Time in Range (Table 2). Additionally, this increase in Time in Range was seen with less effort as evidenced by fewer user-initiated boluses, indicating decreased patient burden.

Table 1: Real-World Evidence of Pediatric Users in Europe, Middle East and Africa & Latin
America (using Recommended Settings)


Europe, Middle East and Africa

Latin America


All Users    15
years

With
Recommended
Settings

All Users    15
years

With
Recommended
Settings

Time in
SmartGuard™
technology

92.7 %

94.6 %

93.5 %

94.9 %

Time in Range

73.9 %

78.9 %

74.2 %

78.2 %

Time Above
Range (> 180
mg/dL)

22.9 %

17.5 %

23.0 %

18.9 %

Table 2: Real-World Evidence of Pediatric Users in Europe (using Recommended Settings)


Group 1

(Lowest
glycemic
control at
initiation)

Group 2

Group 3

Group 4

(Highest glycemic
control at initiation)


Base
line

With
MM780
G

Baseline

With
MM780
G

Baseline

With
MM780
G

Baseline

With
MM780
G

Time in
SmartGuard™
technology

-

89.9 %

-

91.5 %

-

93.2 %

-

91.9 %

Time in Range

41.0 %

64.3 %

55.5 %

69.9 %

65.7 %

73.1 %

79.8 %

80.6 %

Time Above
Range

57.2 %

33.3 %

42 %

27 %

30.9 %

23.8 %

16.6 %

16.5 %

User-initiated
boluses/day

6.3

4.9*

6.6

5.7*

7.0

5.9*

6.7

6.3*

Insulin Units
Delivered by
Auto Correction

14.4

18.0

12.3

14.5

12.0

13.3

10.2

10.9

*Baseline vs post-AHCL number of daily boluses comparison (p

Medtronic Extended Infusion Set Real-World Data

For the first time, real-world data on the Medtronic Extended Infusion™ Set was presented (n=108) and the analysis showed an average infusion set wear time of 6.74 days. Almost half (48.2%) of the individuals evaluated wore the set for 7 days. This real-world data mirrors the results from the U.S. pivotal trial and is delivering a reduced user burden through less frequent infusion set changes.

"We're committed to pushing simplification of diabetes management as far as we can and are heartened to see the impact our MiniMed™ 780G system is having on both clinical and quality of life outcomes as evidenced by our randomized controlled ADAPT study and the growing body of real-world evidence from around the world," said Que Dallara, EVP and President of Medtronic Diabetes. "With each advancement, we're working to reduce more of the burden that this disease demands and will continue to innovate to make life easier for those we have the privilege to support."

About Medtronic Diabetes (   www.medtronicdiabetes.com   )
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About the MiniMed™ 780G system (   www.medtronicdiabetes.com/780G)
The MiniMed™ 780G system is the first system in the world featuring Meal Detection™ technology,* which provides automatic adjustments and corrections to sugar levels every 5 minutes § . The system provides insulin to help account for when users occasionally forget to bolus or underestimate the number of carbs in their meal and features the lowest glucose target setting (as low as 100 mg/dL) in any automated insulin pump on the market, § which more closely mirrors the average glucose of someone not living with diabetes. The MiniMed™ 780G system is approved in the U.S. for individuals with type 1 diabetes, 7 years and above.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.medtronic.com and follow @Medtronic on Twitter and LinkedIn .

*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.
§ Refers to SmartGuard™ feature. Individual results may vary.
**The extended wear infusion set can be worn for up to 7 days. Current infusion sets are recommended for up to 3 days of wear.
‡ Fingersticks required in manual mode & to enter SmartGuard™. If symptoms don't match alerts & readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard™.

  1. Auto corrections help make up for imprecise carb counts.
  2. Medtronic data on file. 25-minute survey, N= 498 T1D individuals in Germany , Japan , US, Brazil , August 2019 .
  3. "Higher Time in Range Demonstrated in Children Using Intensive Advanced Hybrid Closed-Loop (AHCL) System Settings" – poster presentation (1120-P) by Jen McVean , M.D., pediatric endocrinologist, senior director, medical affairs, Medtronic Diabetes on Monday, Jun. 26 at 11:30 a.m. PDT
  4. "Improved Glycemic Control with Less Effort during Real-World MiniMed™ 780G Advanced Hybrid Closed-Loop (AHCL) System Use by Children with T1D" – poster presentation (1119-P) by Jen McVean , M.D., pediatric endocrinologist, senior director, medical affairs, Medtronic Diabetes on Monday, Jun. 26 at 11:30 a.m. PDT

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Contacts:

Janet Cho

Ryan Weispfenning

Public Relations

Investor Relations

+1-818-403-7028

+1-763-505-4626

(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-presents-new-data-on-minimed-780g-system-on-fixed-meal-dosing-and-real-world-time-in-range-across-wide-variety-of-users-301861178.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

MDT
The Conversation (0)
Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. (TSX: PNE) ("Pine Cliff" or the "Company") announces its first quarter 2024 financial and operating results, an operational update and information regarding the annual meeting of shareholders.

First Quarter 2024 Results

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Canadian Natural Resources Limited Announces 2024 First Quarter Results

Canadian Natural's (TSX: CNQ) (NYSE: CNQ) President, Scott Stauth, commented on the Company's first quarter results, "Canadian Natural is a world class company and during our 35 years of operations, we've delivered significant value, including recently reaching a position where, commencing in 2024, we are returning 100% of our free cash flow to our shareholders. Crude oil price forecasts have strengthened for the remainder of 2024, including improvements in West Texas Intermediate ("WTI"), Western Canadian Select ("WCS") and Synthetic Crude Oil ("SCO") pricing over those prices experienced in the first quarter of 2024, driving significant targeted free cash flow generation going forward.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. (TSX: PNE) (OTCQX: PIFYF) ("Pine Cliff" or the "Company") is pleased to announce the appointments of Mr. Daniel Keenan P. Eng to the position of Vice President Exploitation and Mr. Austin Nieuwdorp CA, CPA to the position of Vice President Finance and Controller both effective May 1, 2024.

Mr. Keenan became part of Pine Cliff in 2016. He holds a Bachelor of Mechanical Engineering Degree from the University of Victoria obtained in 2001. Throughout his 20-year career, he has taken on increasingly challenging roles in exploitation, production operations and facilities engineering, culminating in his most recent position as Pine Cliff's Manager of Exploitation. Notably, Mr. Keenan has played a pivotal role in identifying and expanding Pine Cliff's asset portfolio and drilling opportunities, showcasing his leadership and strategic vision.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. (TSX: ACO.X) (TSX: ACO.Y)

2024 ATCO AGM (CNW Group/ATCO Ltd.)

ATCO Ltd. (ATCO) will hold its 57th Annual General Meeting of share owners at 10 a.m. MDT on Wednesday , May 15, 2024. In addition to the formal business of the meeting, attendees will hear management's view of ATCO's full year 2023 and first quarter 2024 operational and financial performance.

At this year's meeting, members of the ATCO executive leadership team will also outline growth strategies and goals for ATCO Structures, ATCO EnPower and ATCO Energy Systems.

Attendees will hear from:

  • Nancy Southern , Chair & Chief Executive Officer
  • Katie Patrick , Executive Vice President, Chief Financial & Investment Officer
  • Adam Beattie , President, ATCO Structures
  • Bob Myles , Chief Operating Officer, ATCO EnPower
  • Wayne Stensby , Chief Operating Officer, ATCO Energy Systems

Share owners and interested parties can view the meeting virtually using Microsoft Teams via this link using a web browser (Chrome, Safari, Edge or Firefox) on a smartphone, tablet or computer. Using Internet Explorer is not recommended as it is no longer supported and may not function properly.

Attendees who are share owners or proxyholders wishing to vote their shares should review the information contained in the ATCO Management Proxy Circular dated March 11, 2024 , beginning on page one.

As a global enterprise ATCO Ltd. and its subsidiary and affiliate companies have approximately 20,000 employees and assets of $25 billion . ATCO is committed to future prosperity by working to meet the world's essential energy, housing, security and transportation challenges. ATCO Structures designs, builds and delivers products to service the essential need for housing and shelter around the globe. ATCO Frontec provides operational support services to government, defence and commercial clients. ATCO Energy Systems delivers essential energy for an evolving world through its electricity and natural gas transmission and distribution, and international operations. ATCO EnPower creates sustainable energy solutions in the areas of renewables, energy storage, industrial water and clean fuels. ATCO Australia develops, builds, owns and operates energy and infrastructure assets. ATCOenergy and Rümi provide retail electricity and natural gas services, home maintenance services and professional home advice that bring exceptional comfort, peace of mind and freedom to homeowners and customers. ATCO also has investments in ports and transportation logistics, the processing and marketing of fly ash, retail food services and commercial real estate. More information can be found at www.ATCO.com .

Investor & Analyst Inquiries:  
Colin Jackson
Senior Vice President, Finance, Treasury & Sustainability
Colin.Jackson@atco.com
(403) 808 2636

Media Inquiries:
Kurt Kadatz
Director, Corporate Communications
Kurt.Kadatz@atco.com
(587) 228 4571

SOURCE ATCO Ltd.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/29/c6613.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces First Quarter 2024 Results, Record Oil Royalty Production

-

PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce its first quarter ("Q1 2024") operating and financial results for the three-month period ended March 31, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO

"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for third quarter of fiscal year 2025

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0 .70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025 to shareholders of record at the close of business on December 27, 2024 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic . Medtronic plc , headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiex Limited (ASX:CDX)

Cardiex Limited


Keep reading...Show less

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation Awareness Day

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC

"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected

FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilitation processes, and efficient hospital logistics, thus attracting more healthcare facilities to adopt robotic solutions. The market is characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for medical service robots. A report from Grand View Research said that the global medical service robots market size was estimated at USD 20.59 billion in 2024 and is projected to grow at a CAGR of 16.5% from 2025 to 2030. It said: "The growth can be attributed to the introduction of technologically advanced robotic equipment in the healthcare sector and the rise in per capita healthcare spending. Continuous advancements in technology, such as robotic catheter control systems (CCS), data recorders, data analytics, remote navigation, motion sensors, 3D-Imaging, and HD surgical microscopic cameras, are projected to drive industry growth. Furthermore, the introduction of swarm robotics is opening new opportunities for industry. It is a new approach to coordinating multi-robotic systems through swarm intelligence." Active Tech Companies in the markets today include Jeffs' Brands Ltd (NASDAQ: JFBR), Serve Robotics Inc. (NASDAQ: SERV), Symbotic Inc. (NASDAQ: SYM), Microbot Medical Inc. (NASDAQ: MBOT), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×